Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740475 | 0.86 | SMN1; SMN2 (0.50) | SMN1; SMN2RAB9AKMT2ANPC1GAA | |
| SCHEMBL14740779 | 0.86 | GAA (0.53) | SMN1; SMN2RAB9AKMT2ANPC1GAA | |
| SCHEMBL14739998 | 0.84 | GAA (0.51) | SMN1; SMN2RAB9AKMT2ANPC1GAA | |
| SCHEMBL14740230 | 0.84 | GAA (0.51) | SMN1; SMN2RAB9AKMT2ANPC1GAA | |
| SCHEMBL14739951 | 0.80 | NPC1 (0.48) | SMN1; SMN2RAB9AKMT2ANPC1MAPK1 | |
| SCHEMBL14740261 | 0.79 | ALDH1A1 (0.55) | SMN1; SMN2RAB9AKMT2ANPC1GAA | |
| SCHEMBL14739782 | 0.79 | DPP4 (0.45) | SMN1; SMN2RAB9AKMT2ANPC1GAA | |
| SCHEMBL14740016 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9AKMT2ANPC1GAA | |
| SCHEMBL14752145 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9AKMT2ANPC1GAA | |
| SCHEMBL14740346 | 0.76 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9AKMT2ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013032939-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR3 | SMN1; SMN2 3151/4885RAB9A 1654/4885KMT2A 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.